Resveratrol may be an effective intervention for Lung Aging

Spread the love
 Inhaled resveratrol treatments slow ageing-related degenerative changes in mouse lung. Thorax, 2017; thoraxjnl-2016-208964 DOI: 10.1136/thoraxjnl-2016-208964

Inhaled, prophylactic resveratrol treatments can slow the rate of lung function decline, alveolar enlargement and alveolar epithelial type 2 cell DNA damage

For the 1st time inhaled resveratrol was shown to slow aging-related degenerative changes in mouse lung. Lung aging, characterized by airspace enlargement and decreasing lung function, is a significant risk factor for chronic human lung diseases. The study is published online in the journal Thorax. Resveratrol (RSL), a chemical found in red wine, is an antimicrobial chemical substance produced by plants to protect against infection and stress-related changes. It has previously been shown to support muscle metabolism when given orally.

RSL prophylaxis by inhalation was a novel measure taken by the research team as a potential approach for slowing age-related deterioration of lung function and structure by preserving alveolar epithelial type 2 cells (AEC2) which line alveoli and produce surfactant which is vital for efficient breathing.

The natural deterioration of lung function leads to a significantly reduced quality of life, over a time frame dependent on genetic and environmental factors. Although some therapies can ameliorate symptoms, aging-related lung failure is generally irreversible and is accompanied by high rates of morbidity and mortality due to increased disease risk, including development of COPD, with accompanying emphysema and chronic bronchitis.

Using a rapidly aging mouse model, the research team investigated whether the accumulation of age-related degenerative changes in the lung could be slowed by inhaled RSL. Treatment cohorts received either RSL or vehicle by intratracheal (IT) instillation monthly for 3 months. One month following the final treatment, whole lung function and injury-related gene expression in AEC2 were assessed.

Inhaled, prophylactic resveratrol treatments can slow the rate of lung function decline, alveolar enlargement and alveolar epithelial type 2 cell DNA damage that occurs in the early stages of lung aging. They concluded tjat administration of resveratrol directly to the lungs may be an effective intervention for lung aging, a significant risk factor for development of chronic lung disease.

“While the natural deterioration of the human lung generally occurs over decades, the injury to lung cells is analogous to the lung cell damage that occurs in premature infants who experience respiratory distress before their lungs have fully developed,” added Driscoll. “Identifying a way to protect and strengthen young lungs before significant damage occurs is the goal of our research.” http://www.chla.org/press-release/resveratrol-may-be-effective-intervention-lung-aging-and-the-ultimate-development

http://thorax.bmj.com/content/early/2017/01/19/thoraxjnl-2016-208964